**Background of MGAT4B Antibody**
The MGAT4B (Mannosyl (Alpha-1.3-)-Glycoprotein Beta-1.4-N-Acetylglucosaminyltransferase, Isozyme B) antibody is a research tool designed to target the MGAT4B enzyme, a key player in N-linked glycan biosynthesis. MGAT4B catalyzes the transfer of N-acetylglucosamine (GlcNAc) to specific mannose residues, forming β1.4-branched structures critical for glycoprotein maturation. This enzyme influences cell-surface receptor signaling, cell adhesion, and immune responses by modulating glycan patterns on proteins.
MGAT4B is implicated in various diseases, particularly cancer. Overexpression of MGAT4B has been observed in tumors such as breast, colon, and lung cancers, where it promotes metastasis by enhancing integrin-mediated cell migration. Its role in altering glycosylation patterns also affects drug resistance and immune evasion.
Antibodies against MGAT4B are widely used in biomedical research to study its expression, localization, and function. Applications include Western blotting, immunohistochemistry (IHC), and flow cytometry to analyze tissue-specific expression or glycosylation changes in disease models. Additionally, MGAT4B antibodies support drug discovery efforts aiming to inhibit aberrant glycosylation in cancer.
Recent studies highlight MGAT4B's potential as a therapeutic target or biomarker, driving demand for high-specificity antibodies. Validation of these antibodies ensures reliability in distinguishing MGAT4B from its isoform MGAT4A, which shares functional overlap but differs in tissue distribution and substrate preference.